• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

    5/23/25 4:01:03 PM ET
    $SLRN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLRN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 2)


    ACELYRIN, INC.

    (Name of Issuer)


    Common Stock, $0.00001 par value

    (Title of Class of Securities)


    00445A100

    (CUSIP Number)


    Alejandro Moreno
    Access Industries, Inc., 40 West 57th St., 28th Floor
    New York, NY, 10019
    (212) 247-6400


    Langhorne S. Perrow
    Access Industries, Inc., 40 West 57th St., 28th Floor
    New York, NY, 10019
    (212) 247-6400


    Nicholas P. Pellicani
    Debevoise & Plimpton LLP, The Northcliffe, 28 Tudor Street
    London, X0, EC4Y 0AY
    44 20 7786 9000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    05/21/2025

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP No.
    00445A100


    1 Name of reporting person

    Access Industries Management, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    00445A100


    1 Name of reporting person

    Access Industries Holdings LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    00445A100


    1 Name of reporting person

    AI ACEL LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    OO



    SCHEDULE 13D

    CUSIP No.
    00445A100


    1 Name of reporting person

    Len Blavatnik
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    0.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    0.00
    11Aggregate amount beneficially owned by each reporting person

    0.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    0 %
    14Type of Reporting Person (See Instructions)

    IN



    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, $0.00001 par value
    (b)Name of Issuer:

    ACELYRIN, INC.
    (c)Address of Issuer's Principal Executive Offices:

    4149 Liberty Canyon Road, Agoura Hills, CALIFORNIA , 91301.
    Item 1 Comment:
    This Amendment No. 2 to Schedule 13D is being filed by Access Industries Management, LLC ("AIM"), Access Industries Holdings LLC ("AIH"), AI ACEL LLC ("AI ACEL"), and Len Blavatnik (collectively, the "Reporting Persons", and each, a "Reporting Person") in respect of common stock, $0.00001 par value per share (the "Common Stock"), of ACELYRIN, INC. (the "Issuer"). The Schedule 13D filed by the Reporting Persons with the SEC on May 19, 2023 (the "Schedule"), as amended and supplemented by Amendment No. 1 to the Schedule 13D filed by the Reporting Persons with the SEC on February 10, 2025, is hereby amended and supplemented by the Reporting Persons as set forth below in this Amendment No. 2. This amendment is filed by the Reporting Persons in accordance with Rule 13d-2 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and refers only to information that has materially changed since the filing of the Schedule. The items identified below, or the particular paragraphs of such items which are identified below, are amended as set forth below. Unless otherwise indicated, all capitalized terms used and not defined herein have the respective meanings assigned to them in the Schedule. This Amendment No. 2 is the final amendment to the Schedule and is an exit filing for the Reporting Persons.
    Item 4.Purpose of Transaction
     
    The information set forth in Item 4 of the Schedule 13D is hereby supplemented to include the following information: On May 21, 2025, pursuant to the Agreement and Plan of Merger, dated as of February 6, 2025, as amended on April 20, 2025 (as amended, the "Merger Agreement"), by and among the Issuer, Alumis Inc., a Delaware corporation ("Alumis") and Arrow Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Alumis ("Merger Sub"), the Issuer completed its merger with Merger Sub, whereby Merger Sub merged with and into the Issuer, in accordance with the General Corporation Law of the State of Delaware, with the Issuer continuing as the surviving corporation and as a wholly owned subsidiary of Alumis (the "Merger"). In connection with the Merger, and upon the terms and subject to the conditions set forth in the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Common Stock issued and outstanding was converted into the right to receive 0.4814 shares of voting common stock of Alumis, par value $0.0001 per share, and cash in lieu of any fractional shares. At the Effective Time, each holder of Common Stock outstanding immediately prior to the Effective Time ceased to have any rights as a stockholder of the Issuer other than the right to receive the consideration for such stockholder's shares of Common Stock under the Merger Agreement. In connection with the closing of the Merger, on May 21, 2025, the Issuer (i) notified The Nasdaq Stock Market LLC ("Nasdaq") that the Merger had been completed and (ii) requested that Nasdaq suspend trading of the Common Stock, effective as of the open of business on May 21, 2025, and filed with the SEC a Form 25, Notification of Removal from Listing and/or Registration, to delist all Common Stock from Nasdaq and deregister the Common Stock under Section 12(b) of the Exchange Act. The Issuer also intends to file a Certification and Notice of Termination of Registration on Form 15 with the SEC requesting the termination of registration of the Common Stock under Section 12(g) of the Exchange Act and the suspension of the Issuer's reporting obligations under Sections 13 and 15(d) of the Exchange Act. As a result of the Merger, on May 21, 2025, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of Common Stock.
    Item 5.Interest in Securities of the Issuer
    (a)
    The information set forth in Item 5(a) of Schedule 13D is hereby amended and restated as follows: The responses of each of the Reporting Persons with respect to Rows 11, 12, and 13 of the cover pages of this Schedule 13D that relate to the aggregate number and percentage of Common Stock (including but not limited to footnotes to such information) are incorporated herein by reference.
    (b)
    The information set forth in Item 5(b) of Schedule 13D is hereby amended and restated as follows: The responses of each of the Reporting Persons with respect to Rows 7, 8, 9, and 10 of the cover pages of this Schedule 13D that relate to the number of Common Stock as to which each of the persons or entities referenced in Item 2 above has sole or shared power to vote or to direct the vote of and sole or shared power to dispose of or to direct the disposition of (including but not limited to footnotes to such information) are incorporated herein by reference. As a result of the Merger, on May 21, 2025, none of the Reporting Persons holds any shares of Common Stock.
    (c)
    The information set forth in Item 5(c) of Schedule 13D is hereby supplemented to incorporate by reference the information set forth in Item 4 above.
    (d)
    On May 21, 2025, each of the Reporting Persons ceased to be the beneficial owner of more than five percent of Common Stock.
    Item 7.Material to be Filed as Exhibits.
     
    99.7 Joint Filing Agreement, dated as of May 23, 2025

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Access Industries Management, LLC
     
    Signature:/s/ Alejandro Moreno
    Name/Title:Executive Vice President, General Counsel/Alejandro Moreno
    Date:05/23/2025
     
    Access Industries Holdings LLC
     
    Signature:/s/ Alejandro Moreno
    Name/Title:By: Access Industries Management, LLC, its manager; its Executive Vice President, General Counsel/Alejandro Moreno
    Date:05/23/2025
     
    AI ACEL LLC
     
    Signature:/s/ Alejandro Moreno
    Name/Title:By: Access Industries Management, LLC, its manager; its Executive Vice President, General Counsel/Alejandro Moreno
    Date:05/23/2025
     
    Len Blavatnik
     
    Signature:*/s/ Alejandro Moreno
    Name/Title:By: Alejandro Moreno as Attorney-in-Fact
    Date:05/23/2025
    Comments accompanying signature:
    *The above signed, by signing his name hereto, executes this Amendment No. 2 to Schedule 13D pursuant to the Limited Power of Attorney executed on behalf of Mr. Blavatnik and filed herewith.
    Get the next $SLRN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLRN

    DatePrice TargetRatingAnalyst
    8/14/2024$18.00 → $6.00Buy → Neutral
    H.C. Wainwright
    7/8/2024$13.00Equal Weight → Overweight
    Wells Fargo
    12/13/2023$11.00Equal Weight
    Wells Fargo
    12/8/2023$8.00Neutral
    Citigroup
    9/13/2023$19.00Overweight → Equal-Weight
    Morgan Stanley
    9/5/2023$44.00Buy
    H.C. Wainwright
    5/30/2023Overweight
    Morgan Stanley
    5/30/2023$31.00Buy
    Jefferies
    More analyst ratings

    $SLRN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Alumis Stockholders Approve Merger with ACELYRIN

      SOUTH SAN FRANCISCO, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today announced that its stockholders voted to approve all proposals required to be approved in connection with the pending merger with ACELYRIN, INC. (NASDAQ:SLRN) at its Special Meeting of Stockholders. Martin Babler, President, Chief Executive Officer and Chairman of Alumis, said, "We thank our stockholders for their support for the merger and with this milestone now complete, we are moving expeditious

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN Stockholders Approve Merger with Alumis to Create Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      LOS ANGELES, May 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, Inc. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that at the Company's special meeting of stockholders held earlier today, its stockholders voted to approve the adoption of the Company's merger agreement with Alumis Inc. (NASDAQ:ALMS). As previously announced, under the terms of the amended merger agreement, ACELYRIN stockholders will receive 0.4814 shares of Alumis common stock for each share of ACELYRIN common stock owned at the closing of the transaction. "We appreciate our stockholders' support for our merger

      5/13/25 1:00:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Leading Independent Proxy Advisory Firm ISS Recommends ACELYRIN Stockholders Vote "FOR" the Proposed Transaction with Alumis

      ACELYRIN Urges Stockholders to Vote FOR the Proposed Transaction Today LOS ANGELES, May 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that leading independent proxy advisory firm Institutional Shareholder Services ("ISS") has recommended that ACELYRIN stockholders vote "FOR" the proposed merger ("Proposed Transaction") of the Company with Alumis Inc. (NASDAQ:ALMS). The Company's special meeting of stockholders to vote on the Proposed Transaction is scheduled for May 13, 2025. ACELYRIN urges its stockholders to vote FOR the Pr

      5/6/25 4:30:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ACELYRIN downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded ACELYRIN from Buy to Neutral and set a new price target of $6.00 from $18.00 previously

      8/14/24 7:48:43 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN upgraded by Wells Fargo with a new price target

      Wells Fargo upgraded ACELYRIN from Equal Weight to Overweight and set a new price target of $13.00

      7/8/24 8:17:02 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wells Fargo initiated coverage on ACELYRIN with a new price target

      Wells Fargo initiated coverage of ACELYRIN with a rating of Equal Weight and set a new price target of $11.00

      12/13/23 8:08:18 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Leadership Updates

    Live Leadership Updates

    See more
    • Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

      Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ:AVTX) today announced it has acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio, Inc. Concurrent with the acquisition, Ava

      3/27/24 4:01:00 PM ET
      $AVTX
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications

      Highly accomplished leader bringing more than 25 years of investor relations, communications, and operational & strategic finance experience at public healthcare companies LOS ANGELES, Feb. 15, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Agnes Lee as Senior Vice President, Investor Relations and Corporate Communications. Reporting to Founder and CEO Shao-Lee Lin, MD, PhD, Ms. Lee will be responsible for leading investor relations and corporate communications and will join the company's Senior Leadership Team.

      2/15/24 4:05:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Appoints Lynn Tetrault to Board of Directors

      LOS ANGELES, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced the appointment of Lynn Tetrault to its board of directors. "I am pleased to welcome Lynn to our board of directors as we close our first year as a publicly traded company. Lynn is a highly accomplished biopharma executive and her extensive expertise spanning global human capital strategy, talent management, business operations, and corporate affairs adds a valuable dimension to support our evolving company," said Shao-Lee Lin, MD, PhD, Founder and CEO of ACELYRIN

      12/20/23 4:30:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

      SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

      5/23/25 4:15:26 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by ACELYRIN INC.

      SCHEDULE 13D/A - ACELYRIN, Inc. (0001962918) (Subject)

      5/23/25 4:01:03 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by ACELYRIN INC.

      EFFECT - ACELYRIN, Inc. (0001962918) (Filer)

      5/23/25 12:15:04 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Financials

    Live finance-specific insights

    See more
    • ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

      LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology, today announced that, in response to Tang Capital Partners' continued rapid accumulation of 8.8% of ACELYRIN'S outstanding common stock, its Board of Directors has approved the adoption of a limited-duration stockholder rights plan ("Rights Plan"). The ACELYRIN Board and management team continue to engage with stockholders and are focused on maximizing stockholder value. Pursuant to the Rights Plan, the Company is issuing one right for each share of common stock as of the close

      3/13/25 7:00:00 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alumis and ACELYRIN to Merge Creating a Late-Stage Clinical Biopharma Company Dedicated to Innovating, Developing and Commercializing Transformative Therapies for Immune-mediated Diseases

      Topline data from Phase 3 ONWARD trials for Alumis' ESK-001 in moderate-to-severe plaque psoriasis on track for readout in first half of 2026; Topline data from Phase 2b LUMUS trial in systemic lupus erythematosus on track for readout in 2026 Evaluation underway of development plan for ACELYRIN's lonigutamab to confirm differentiation in a capital efficient manner Pro forma cash position of approximately $737 million as of December 31, 2024, provides runway into 2027, beyond expected multiple clinical readouts for highly differentiated late-stage portfolio Alumis and ACELYRIN stockholders to own ~55% and ~45%, respectively, of combined company on a fully diluted basis Combined company wi

      2/6/25 4:15:00 PM ET
      $ALMS
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

      Totality of data observed with subcutaneous lonigutamab in Thyroid Eye Disease (TED) patients demonstrate potential for efficacy in line with standard of care and a more favorable safety profile Conducted positive end of Phase 2 FDA meeting; Phase 3 program expected to be initiated in Q1 2025 Topline Phase 3 data expected in second half of 2026; cash runway expected through mid-2027 Conference call to review unmet need in TED, new Phase 2 data and Phase 3 program design to be held today, January 6, 2025, at 4:30 PM ET LOS ANGELES, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (NASDAQ:SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery

      1/6/25 4:00:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Ayurmaya Capital Management Company, Lp returned 9,334,735 shares to the company (SEC Form 4)

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:23:20 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Executive Officer Kim Mina was granted 89,526 shares and returned 770,833 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:11:54 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cozadd Bruce C

      4 - ACELYRIN, Inc. (0001962918) (Issuer)

      5/23/25 4:11:07 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLRN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

      SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

      11/14/24 1:28:35 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by ACELYRIN INC.

      SC 13G/A - ACELYRIN, Inc. (0001962918) (Subject)

      11/12/24 12:13:00 PM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ACELYRIN INC.

      SC 13G - ACELYRIN, Inc. (0001962918) (Subject)

      11/4/24 10:56:23 AM ET
      $SLRN
      Biotechnology: Pharmaceutical Preparations
      Health Care